Evidence map›Paper›PMID 28277487›Full record

Trial reportJournal of acquired immune deficiency syndromes (1999)2017

Randomized Controlled Trial of an Intervention to Maintain Suppression of HIV Viremia After Prison Release: The imPACT Trial.

David A Wohl, Carol E Golin, Kevin Knight, Michele Gould, Jessica Carda-Auten, Jennifer S Groves, Sonia Napravnik, Stephen R Cole, Becky L White, Cathie Fogel and 4 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of acquired immune deficiency syndromes (1999), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Frequency and Duration of Incarceration and Mortality Among US Veterans With and Without HIV.Journal of acquired immune deficiency syndromes (1999) · 2020
    Article
  15. Review
  16. Article
  17. Observational
  18. Prisons: ignore them at our peril.Current opinion in HIV and AIDS · 2019
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

David A Wohl*The Institute for Global Health and Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, NC; †The Institute of Behavioral Research, Texas Christian University, Fort Worth, TX; and ‡Division of Infectious Diseases, The University of Alabama School of Medicine, Birmingham, AL.
Carol E Golin
Kevin Knight
Michele Gould
Jessica Carda-Auten
Jennifer S Groves
Sonia Napravnik
Stephen R Cole
Becky L White
Cathie Fogel
David L Rosen
Michael J Mugavaro
Brian W Pence
Patrick M Flynn

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Justice Community Opioid Innovation Network (JCOIN): TCU Clinical Research CenterUG1DA050074 · NIDA · TEXAS CHRISTIAN UNIVERSITY · PI KNIGHT, DANICA K, KNIGHT, KEVIN · 2019 to 2023
$10.1M
RCT of an augmented test, treat, link, & retain model for NC and Texas prisonersR01DA030793 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FLYNN, PATRICK M, GOLIN, CAROL E · 2010 to 2015
$6.9M
Mentoring New Investigators in Criminal Justice HIV Prevention and TreatmentK24DA037101 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOHL, DAVID A · 2014 to 2018
$911k
Enhancing HIV screening Among Primary care physicians in the SoutheastK23MH094250 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WHITE, BECKY L · 2012 to 2016
$884k
Mentoring Junior Investigators: Comprehensive HIV PreventionK24HD069204 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GOLIN, CAROL E · 2013 to 2017
$789k
NIAID NIH HHS P30 AI050410NICHD NIH HHS K24 HD069204NIDA NIH HHS K24 DA037101NIDA NIH HHS R01 DA030793NIMH NIH HHS K23 MH094250
6 · The paper itself

Abstract

backgroundHIV-infected individuals transitioning from incarceration to the community are at risk for loss of viral suppression. We compared the effects of imPACT, a multidimensional intervention to promote care engagement after release, to standard care on sustaining viral suppression after community re-entry.

methodsThis trial randomized 405 HIV-infected inmates being released from prisons in Texas and North Carolina with HIV-1 RNA levels <400 copies/mL to imPACT versus standard care. The imPACT arm received motivational interviewing prerelease and postrelease, referral to care within 5 days of release, and a cellphone for medication text reminders. The standard care arm received routine discharge planning and a cellphone for study staff contact. The primary outcome was the difference between arms in week 24 postrelease viral suppression (HIV-1 RNA <50 copies/mL) using intention-to-treat analysis with multiple imputation of missing data.

resultsThe proportion with 24-week HIV-1 RNA <50 copies/mL was 60% and 61% in the imPACT and standard care arms, respectively [odds ratio for suppression 0.95 (95% confidence interval: 0.59 to 1.53)]. By week 6 postrelease, 86% in the imPACT arm versus 75% in the standard care arm attended at least 1 nonemergency clinic visit (P = 0.02). At week 24, 62% in both arms reported not missing any antiretroviral doses in the past 30 days (P > 0.99).

conclusionsHigher rates of HIV suppression and medical care engagement than expected based on previous literature were observed among HIV-infected patients with suppressed viremia released from prison. Randomization to a comprehensive intervention to motivate and facilitate HIV care access after prison release did not prevent loss of viral suppression. A better understanding of the factors influencing prison releasees' linkage to community care, medication adherence, and maintenance of viral suppression is needed to inform policy and other strategic approaches to HIV prevention and treatment.

Indexed as

Behavior TherapyMedication AdherenceSustained Virologic ResponseAdultAnti-Retroviral AgentsFemaleHIV InfectionsHumansMaleMiddle AgedNorth CarolinaPrisonersPrisonsTexasAnti-Retroviral Agents

Identifiers

PMID28277487
PMCPMC5443668

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.